Bain buys $50M stake in newly public blood disorder company Disc Medicine

When the sale wraps up on Wednesday, Bain will be Disc’s largest institutional shareholder, based on a review of publicly available filings. The Boston-based investment firm contributed $50 million to the consortium through its life sciences arm.